Department of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.
Asia Pac J Clin Oncol. 2022 Jun;18(3):171-176. doi: 10.1111/ajco.13378. Epub 2020 Jun 23.
Lung cancer has been the leading cause of cancer-related death for decades and years. For the patients with early stage non-small cell lung cancer, surgical resection is the mainstay of therapy. Treatment before and after surgery, such as chemotherapy, can bring benefit to these patients, improving the 5 years survival rate by 5% approximately. Recently, the advent of immunotherapy significantly improved prognosis for the patient with lung cancer. Programmed death 1 and its ligand have become a powerful treatment option for lung cancer. In this review, we will discuss the role immunotherapy played in preoperative neoadjuvant and postoperative adjuvant treatment in lung cancer.
几十年来，肺癌一直是癌症相关死亡的主要原因。对于早期非小细胞肺癌患者，手术切除是主要的治疗方法。手术前后的治疗，如化疗，可以为这些患者带来益处，使 5 年生存率提高约 5%。最近，免疫疗法的出现显著改善了肺癌患者的预后。程序性死亡 1 及其配体已成为肺癌的一种强有力的治疗选择。在这篇综述中，我们将讨论免疫疗法在肺癌术前新辅助治疗和术后辅助治疗中的作用。
